This site is intended for U.S. healthcare professionals.
Phase III Study Primary Endpoints
Phase III Study Secondary Endpoints
Many patients have access to EUCRISA without restriction or after a trial of one plan-designated topical corticosteroid†
Learn about cost and coverage options in your area.* Enter a ZIP code below to determine the cost and coverage of EUCRISA.
Patients in your area have access to EUCRISA without restriction or after a trial of one plan-designated topical corticosteroid†
*Eligible patients pay as little as $10
A savings and support program for your patients to help them with their access to EUCRISA
Register or sign in to check availability and request samples.
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.
EUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Warnings and Precautions
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.
Please see Full Prescribing Information and Patient Information